Navigation Links
Alfacell Receives NASDAQ Delisting Letter
Date:8/1/2008

nce in support of the Company's position at the hearing.

As disclosed in the Company's press releases on July 18, 2008 and June 26, 2008, the Company has also failed to comply with the $1 minimum bid price requirement under Marketplace Rule 4310(c)(4), the $2.5 million minimum stockholders' equity requirement under Marketplace Rule 4310(c)(3)(A) and the requirement for a minimum net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years under Marketplace Rule 4310(c)(3)( C). For continued listing on The NASDAQ Capital Market, the Company must comply with, among other requirements, at least one of the three alternative listing standards (market value, stockholders' equity or net income) and the minimum bid price requirement.

The Company is currently considering actions that may allow it to regain compliance with the NASDAQ continued listing standards and maintain its NASDAQ listing.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of ONCONASE in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Alfacell Receives NASDAQ Non-Compliance Notification
2. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
3. Alfacell Announces Retirement of Chief Executive Officer
4. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
5. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
6. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
7. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Alfacell to Present at BIO InvestorForum 2007
10. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
11. Workforce Alliance Receives U.S. Labor Departments Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
(Date:12/10/2009)... Corporation (Nasdaq: DNDN ) announced today that it ... of its common stock at a price to the ... to the underwriters a 30-day option to purchase up ... cover overallotments, if any. The offering is expected ... closing conditions. ,, J. P. Morgan Securities Inc. and ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
... , , ... , , , , ... protein from human melanoma cell lines [1]. MIA,is expressed in and ... chondrocytes,is dependent on the differentiation status of the cells,it was also ...
... , , , ... , Abstract , ... The efficiency of the Rapid DNA Ligation Kit from,Roche Molecular ... DNA in a three-fragment assembly,DNA ligation. Sequential blunt-end and cohesive-end,ligation, including a temperature ...
... , ... , , Roche Applied Science was ... move away from the use of hazardous,radioactive isotopes. Even after 15 ... technologies, the,DIG System remains THE nonradioactive technology of,choice to label and ...
Other Biology Technology:Quantitation of the Protein MIA as a Marker for,Chondrocytes in Research Samples 2Quantitation of the Protein MIA as a Marker for,Chondrocytes in Research Samples 3Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 2Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 3Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 4The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 2The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 3The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 4The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 5
(Date:12/11/2009)... studying how bacteria under stress collectively weigh and initiate ... into how humans make strategic decisions that affect their ... , Their study, published this week in the early ... National Academy of Sciences , was accomplished when the ... describe the complex interplay of genes and proteins that ...
(Date:12/11/2009)... New discoveries about the deep ocean,s temperature variability and ... conditions. , The deep ocean is affected more by ... for more accurate predictions of factors such as sea ... surface temperatures have also been found to result in ... results in a faster transport of large quantities of ...
(Date:12/11/2009)... is a health risk but why do teens become ... evaluation for Faculty of 1000 Biology, Neil Grunberg looks ... , Grunberg describes the study, published by Natividad et ... suggests it "may have implications to help understand why ... increases the level of dopamine in the brain, a ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5New discoveries could improve climate projections 2TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 1TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 2TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 3TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 4Swine Flu Loves a Crowd 57482 1Swine Flu Loves a Crowd 57482 2Swine Flu Loves a Crowd 57482 3Swine Flu Loves a Crowd 57482 4Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference 57478 1Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference 57478 2
... In order to increase productivity, forest practices have become ... 800% in the southeastern United States from 1990 to ... exceeds the forest area fertilized in the rest of ... practices, including fertilization, may negatively impact water quality in ...
... a host of threats that can result in fetal/neonatal ... issue of the American Journal of Obstetrics & Gynecology, ... the Drexel University College of Medicine found that genital ... 23% of neonates born between 23 and 32 weeks ...
... identified a key factor that determines the ability of ... respiratory tracta necessary step for sustaining spread between people. ... of Nature Biotechnology and funded by the National Institutes ... H5N1 avian flu virus currently circulating in birds would ...
Other Biology News:Will intensive forest practices impact water quality? 2Bacterial infections in premature babies more common than previously realized 2Study of sugars on cell surface identifies key factor in flu infection 2Study of sugars on cell surface identifies key factor in flu infection 3
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Expansion Kit - Monolayer Plus is a system ... as a monolayer in a serum-free environment. The ... Supplement, which has been optimized for neural stem ... (1996) Genes & Development 10 :3129). Human ...
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
Biology Products: